



(51) International Patent Classification:

C07K 16/28 (2006.01) *A61K 38/46* (2006.01)
A61P 29/00 (2006.01) *A61P 35/00* (2006.01)
A61K 35/17 (2015.01) *A61P 37/02* (2006.01)

(21) International Application Number:

PCT/US2020/017518

(22) International Filing Date:

10 February 2020 (10.02.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:


201941005395 11 February 2019 (11.02.2019) IN

(71) Applicant: **ZUMUTOR BIOLOGICS INC.** [US/US];
CIC Cambridge Campus, 1 Broadway, Cambridge, Massachusetts 02142 (US).

(72) Inventors: **RODRIGUES, Kavitha Iyer**; c/o Zumutor Biologics Inc., CIC Cambridge Campus, 1 Broadway, Cambridge, Massachusetts 02142 (US). **GHOSH, Malay**; c/o Zumutor Biologics Inc., CIC Cambridge Campus, 1 Broadway, Cambridge, Massachusetts 02142 (US). **MAITY, Sunit**; c/o Zumutor Biologics Inc., CIC Cambridge Campus, 1 Broadway, Cambridge, Massachusetts 02142 (US). **MUNIRAJU, Yogendra Manjunath Bangalore**; c/o Zumutor Biologics Inc., CIC Cambridge Campus, 1 Broadway, Cambridge, Massachusetts 02142 (US). **MURUGESAN, Sathyabalan**; c/o Zumutor Biologics Inc., CIC Cambridge Campus, 1 Broadway, Cambridge, Mass-

achusetts 02142 (US). **BHATTACHARJEE, Sanghamitra**; c/o Zumutor Biologics Inc., CIC Cambridge Campus, 1 Broadway, Cambridge, Massachusetts 02142 (US). **HALAN, Vivek**; c/o Zumutor Biologics Inc., CIC Cambridge Campus, 1 Broadway, Cambridge, Massachusetts 02142 (US). **CHAKRABARTY, Subhra Prakash**; c/o Zumutor Biologics Inc., CIC Cambridge Campus, 1 Broadway, Cambridge, Massachusetts 02142 (US). **DUBEY, Ashvini Kumar**; c/o Zumutor Biologics Inc., CIC Cambridge Campus, 1 Broadway, Cambridge, Massachusetts 02142 (US). **TIWARI, Anurag**; c/o Zumutor Biologics Inc., CIC Cambridge Campus, 1 Broadway, Cambridge, Massachusetts 02142 (US). **SINDHE, Kirthana Mysore Vasudevvarao**; c/o Zumutor Biologics Inc., CIC Cambridge Campus, 1 Broadway, Cambridge, Massachusetts 02142 (US). **LAHIRI, Pallavi**; c/o Zumutor Biologics Inc., CIC Cambridge Campus, 1 Broadway, Cambridge, Massachusetts 02142 (US). **RAO, Sahana Bhima**; c/o Zumutor Biologics Inc., CIC Cambridge Campus, 1 Broadway, Cambridge, Massachusetts 02142 (US). *****, **Prachi**; c/o Zumutor Biologics Inc., CIC Cambridge Campus, 1 Broadway, Cambridge, Massachusetts 02142 (US). **SRIVASTAVA, Shruti**; c/o Zumutor Biologics Inc., CIC Cambridge Campus, 1 Broadway, Cambridge, Massachusetts 02142 (US). **RAMESH, Rao Shreesha**; c/o Zumutor Biologics Inc., CIC Cambridge Campus, 1 Broadway, Cambridge, Massachusetts 02142 (US). **SHENOY, Bharath Ravindra**; c/o Zumutor Biologics Inc., CIC Cambridge Campus, 1 Broadway, Cambridge, Massachusetts 02142 (US). **MARKANDA, Nikitha**; c/o Zumutor Biologics Inc., CIC Cambridge

(54) Title: ANTI-CLEC2D ANTIBODIES AND METHODS OF USE THEREOF



(57) Abstract: The present application disclosure relates to anti-CLEC2D (CLEC2D encodes the gene for the Lectin Like Transcript-1-LLT1- protein which is a functional ligand for the human NKR-PIA receptor) antibodies and related compositions and methods of use thereof. These antibodies are used as therapeutics, and in prognostic and diagnostic applications in various cancers and other diseases.

[Continued on next page]



Campus, 1 Broadway, Cambridge, Massachusetts 02142 (US). **DIKEY, Bhagyashree**; c/o Zumutor Biologics Inc., CIC Cambridge Campus, 1 Broadway, Cambridge, Massachusetts 02142 (US). **NATARAJAN, Bairavabalakumar**; c/o Zumutor Biologics Inc., CIC Cambridge Campus, 1 Broadway, Cambridge, Massachusetts 02142 (US).

(74) **Agent: CHEN, Chen** et al.; Cooley LLP, 1299 Pennsylvania Avenue, NW, Suite 700, Washington, District of Columbia 20004 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*